Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Heron Therapeutics Inc (NASDAQ:HRTX)

17.46
Delayed Data
As of 4:00pm ET
 +0.26 / +1.51%
Today’s Change
15.22
Today|||52-Week Range
42.25
-34.61%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$630.5M

Company Description

Heron Therapeutics, Inc. is a biotechnology company develops pharmaceutical products for patients suffering from cancer or pain. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its primary products are SUSTOL, HTX-019 and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA

Contact Information

Heron Therapeutics, Inc.
123 Saginaw Drive
Redwood City California 94063
P:(650) 366-2626
Investor Relations:
(858) 703-6063

Employees

Shareholders

Mutual fund holders66.49%
Other institutional61.87%
Individual stakeholders22.04%

Top Executives

Barry D. QuartChief Executive Officer & Director
Robert H. RosenPresident, Director & Chief Commercial Officer
Michael A. AdamSenior VP-Regulatory Affairs & Quality
Brian G. DrazbaVP, Chief Financial & Accounting Officer
Thomas B. OttoboniSVP-Pharmaceutical, Research & Development